Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$1.23 USD
-0.02 (-1.58%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.20 -0.03 (-2.44%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APTO 1.23 -0.02(-1.58%)
Will APTO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APTO
What Makes Aptose Biosciences (APTO) a New Buy Stock
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
Other News for APTO
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Aptose Reports Results for the Fourth Quarter and Full Year 2023